Cellular senescence and cancer chemotherapy resistance
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Innate or acquired resistance to cancer therapeutics remains an important area of biomedical investigation that has clear ramifications for improving cancer specific death rates. Importantly, clues to key resistance mechanisms may lie in the well-orchestrated and highly conserved cellular and systemic responses to injury and stress. Many anti-neoplastic therapies typically rely on DNA damage, which engages potent DNA damage response signaling pathways that culminate in apoptosis or growth arrest at checkpoints to allow for damage repair. However, an alternative cellular response, senescence, can also be initiated when challenged with these internal/external pressures and in ideal situations acts as a self-protecting mechanism. Senescence-induction therapies are an attractive concept in that they represent a normal, highly conserved and commonly-invoked tumor-suppressing response to overwhelming genotoxic stress or oncogene activation. Yet, such approaches should ensure that senescence by-pass or senescence re-emergence does not occur, as emergent cells appear to have highly drug resistant phenotypes. Further, cell non-autonomous senescence responses may contribute to therapy-resistance in certain circumstances. Here we provide an overview of mechanisms by which cellular senescence plausibly contributes to therapy resistance and concepts by which senescence responses can be influenced to improve cancer treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The serial cultivation of human diploid cell strains
Hayflick, L., & Moorhead, P. S. (1961) · Experimental Cell Research · doi:10.1016/0014-4827(61)90192-6 · Cited by 8,508 · cited 1×
“The earliest described initiator was replicative exhaustion (Hayflick and Moorhead, 1961).”
BackgroundThe DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092 · cited 1×
“There are several factors that can induce the damage response ranging from UV exposure to commonly used cancer treatments such as γ-radiation and chemotherapeutics (reviewed by (Jackson and Bartek, 2009)).”
BackgroundOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“Early cell based assays found that enhanced expression of the oncogene RAS resulted in stable cellular arrest and that this state was achieved via accumulation of p53 and p16 (Serrano et al., 1997).”
BackgroundThe DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368 · cited 3×
“The first of which, if feasible is that it can lead to the activation of the repair mechanisms which if achieved can allow the cell to attain normal functions (Ciccia and Elledge, 2010; Riley et al., 2008).”
BackgroundThe DNA damage response: putting checkpoints in perspective
Zhou, B.-B. S., & Elledge, S. J. (2000) · Nature · doi:10.1038/35044005 · Cited by 3,213
A DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917 · cited 2×
“There is also an activation of Chk1 and Chk2, modifications of p53, induction of p21 and p16 and the consequential arrest of cell cycle progression (d'Adda di Fagagna et al., 2003; Gewirtz et al., 2008).”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 2×
“There have been reports both supporting immune mediated attrition (Xue et al., 2007) and the continued accretion of senescent cells in vivo (Dimri et al.”
BackgroundPersistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
Rodier, F., Coppé, J.-P., Patil, C. K., Hoeijmakers, W. A. M., Muñoz, D. P., Raza, S. R., Freund, A., Campeau, E., Davalos, A. R., & Campisi, J. (2009) · Nature Cell Biology · doi:10.1038/ncb1909 · Cited by 2,232
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160 · cited 3×
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript Upregulated expression or activating mutations of BRAF in melanocytes also results in a shift to a senescence phenotype (Michaloglou et al., 2005).”
BackgroundOncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network
Kuilman, T., Michaloglou, C., Vredeveld, L. C. W., Douma, S., van Doorn, R., Desmet, C. J., Aarden, L. A., Mooi, W. J., & Peeper, D. S. (2008) · Cell · doi:10.1016/j.cell.2008.03.039 · Cited by 2,086 · cited 2×
“Comprehensive studies of transcriptional responses to genotoxic stress induced by cancer therapeutics have identified a spectrum of highly-induced secreted proteins originating in the tumor microenvironment that comprise several hundred factors (Bavik et al., 2006; Coppe et al., 2008; Kuilman et al., 2008).”
BackgroundCrucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986 · cited 1×
“The ATM pathway has also been implicated in initiating a senescence response following perturbation of the oncogenes mos, cdc6 and Cyclin E (Bartkova et al., 2006).”
BackgroundTranscriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921 · cited 3×
“However, if the cell is beyond repair, other avenues following p53 activation such as the upregulation of proapoptotic proteins or the activation of p21 which then interferes with cyclin-dependent kinase activity resulting in permanent cell cycle arrest and a state of senescence, will be engaged (Gewirtz et al., 2008;…”
BackgroundOncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication
Di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C., Schurra, C., Garre’, M., Giovanni Nuciforo, P., Bensimon, A., et al. (2006) · Nature · doi:10.1038/nature05327 · Cited by 1,821 · cited 1×
“Additionally, in certain situations overexpression of oncogenes can lead to hyper proliferation and as a result, activation of the cellular senescence response (Di Micco et al., 2006).”
BackgroundRestoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“In cell based assays the artificial activation of p53 triggered tumor-specific apoptosis and senescence (Ventura et al., 2007).”
BackgroundCellular senescence in cancer and aging.
Collado, M., Blasco, M. A., & Serrano, M. (2007) · Cell · doi:10.1016/j.cell.2007.07.003 · Cited by 1,708
The DNA Damage Response: Ten Years After
Harper, J. W., & Elledge, S. J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.015 · Cited by 1,705 · cited 1×
“The activation of ATM has several effects, one of which leads to the phosphorylation of serine 139 on H2AX, which plays a role in the accumulation of MDC1 at the site of damage (Ciccia and Elledge, 2010; Harper and Elledge, 2007).”
BackgroundReversal of human cellular senescence: roles of the p53 and p16 pathways
Beauséjour, C. M., Krtolica, A., Galimi, F., Narita, M., Lowe, S. W., Yaswen, P., & Campisi, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg417 · Cited by 1,457
ATM Activation by DNA Double-Strand Breaks Through the Mre11-Rad50-Nbs1 Complex
Lee, J.-H., & Paull, T. T. (2005) · Science · doi:10.1126/science.1108297 · Cited by 1,424 · cited 1×
“The initiation of the DDR is mediated by sensor proteins (Zhou and Elledge, 2000), such as the Mre11-Rad50-Nbs1 (MRN) mediator complex (Lee and Paull, 2005; Paull and Lee, 2005).”
BackgroundOncogene-induced senescence as an initial barrier in lymphoma development
Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A. H. F. M., Schlegelberger, B., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A. (2005) · Nature · doi:10.1038/nature03841 · Cited by 1,220
Senescence in tumours: evidence from mice and humans
Collado, M., & Serrano, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2772 · Cited by 1,124 · cited 1×
“In addition to the visible physical changes there is an increased activity of senescence associated β-galactosidase present within the cells (Collado and Serrano, 2010).”
BackgroundAutophagy mediates the mitotic senescence transition
Young, A. R. J., Narita, M., Ferreira, M., Kirschner, K., Sadaie, M., Darot, J. F. J., Tavaré, S., Arakawa, S., Shimizu, S., Watt, F. M., et al. (2009) · Genes & Development · doi:10.1101/gad.519709 · Cited by 1,078
Chien, Y., Scuoppo, C., Wang, X., Fang, X., Balgley, B., Bolden, J. E., Premsrirut, P., Luo, W., Chicas, A., Lee, C. S., et al. (2011) · Genes & Development · doi:10.1101/gad.17276711 · Cited by 1,046
Freund, A., Patil, C. K., & Campisi, J. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.69 · Cited by 1,039 · cited 4×
“The logical therapeutic opportunity is to either inhibit individual components of the SASP or DDSP, or target master regulators of the response that transduce the DDR signal to promote the production of these effector proteins.”
BackgroundInfluentialA p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity
Marión, R. M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., Fernandez-Capetillo, O., Serrano, M., & Blasco, M. A. (2009) · Nature · doi:10.1038/nature08287 · Cited by 1,028 · cited 2×
“, 2011; Janssens and Tschopp, 2006), p53 (Marion et al., 2009), IL-1alpha (Orjalo et al.”
BackgroundSenescence-messaging secretome: SMS-ing cellular stress
Kuilman, T., & Peeper, D. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2560 · Cited by 909 · cited 2×
“Collectively, this attribute of senescent cells involving secreted factors has been termed a Senescence Associated Secretory Phenotype (SASP) (Freund et al., 2011), Senescence-Messaging Secretome (SMS) (Kuilman and Peeper, 2009), or DNA Damage associated Secretory Program (DDSP).”
BackgroundAwakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 1×
“Subsequent reports have suggested that p53 activation/stabilization could be used as a potential mechanism to push tumors into a senescent state (Brown et al., 2009; Kortlever et al., 2006).”
BackgroundMicroarray analysis of replicative senescence
Shelton, D. N., Chang, E., Whittier, P. S., Choi, D., & Funk, W. D. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80420-5 · Cited by 764
Orjalo, A. V., Bhaumik, D., Gengler, B. K., Scott, G. K., & Campisi, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905299106 · Cited by 654
Kortlever, R. M., Higgins, P. J., & Bernards, R. (2006) · Nature Cell Biology · doi:10.1038/ncb1448 · Cited by 637 · cited 1×
“Subsequent reports have suggested that p53 activation/stabilization could be used as a potential mechanism to push tumors into a senescent state (Brown et al., 2009; Kortlever et al., 2006).”
BackgroundAcute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry
Sage, J., Miller, A. L., Pérez-Mancera, P. A., Wysocki, J. M., & Jacks, T. (2003) · Nature · doi:10.1038/nature01764 · Cited by 538 · cited 2×
“Furthermore, other investigators found that acute loss of RB1 in senescent cells promoted a reversal of the senescent phenotype (Sage et al., 2003).”
BackgroundHallmarks of senescence in carcinogenesis and cancer therapy
Shay, J. W., & Roninson, I. B. (2004) · Oncogene · doi:10.1038/sj.onc.1207518 · Cited by 502 · cited 1×
“This is based on the idea that tumor cells remain prone to senescence and that they are readily induced into this phenotype following treatment with chemotherapeutics and ionizing radiation (Roninson, 2003; Shay and Roninson, 2004).”
BackgroundA negative feedback signaling network underlies oncogene-induced senescence
Courtois-Cox, S., Genther Williams, S. M., Reczek, E. E., Johnson, B. W., McGillicuddy, L. T., Johannessen, C. M., Hollstein, P. E., MacCollin, M., & Cichowski, K. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.003 · Cited by 501 · cited 1×
“Furthermore, inactivation of tumor suppressors, such as PTEN and NF1 appear to also initiate a senescence response (Chen et al., 2005; Courtois-Cox et al., 2006).”
BackgroundKurz, D. J., Decary, S., Hong, Y., Trivier, E., Akhmedov, A., & Erusalimsky, J. D. (2004) · Journal of Cell Science · doi:10.1242/jcs.01097 · Cited by 499
Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis
Sarkisian, C. J., Keister, B. A., Stairs, D. B., Boxer, R. B., Moody, S. E., & Chodosh, L. A. (2007) · Nature Cell Biology · doi:10.1038/ncb1567 · Cited by 490 · cited 1×
“There is also evidence that mutations in RAS family members, leading to their altered expression, can aid in the evasion of p53mediated senescence signaling cascades (Sarkisian et al., 2007).”
BackgroundBavik, C., Coleman, I., Dean, J. P., Knudsen, B., Plymate, S., & Nelson, P. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1716 · Cited by 453
Self-citationPro-senescence therapy for cancer treatment
Nardella, C., Clohessy, J. G., Alimonti, A., & Pandolfi, P. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3057 · Cited by 437
Roberson, R. S., Kussick, S. J., Vallieres, E., Chen, S.-Y. J., & Wu, D. Y. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1270 · Cited by 428
DNA Damage-Mediated Induction of a Chemoresistant Niche
Gilbert, L. A., & Hemann, M. T. (2010) · Cell · doi:10.1016/j.cell.2010.09.043 · Cited by 428 · cited 1×
“Suppression of these pro-survival factors resulted in enhanced tumor cell killing (Gilbert and Hemann, 2010).”
BackgroundChoudhury, A. R., Ju, Z., Djojosubroto, M. W., Schienke, A., Lechel, A., Schaetzlein, S., Jiang, H., Stepczynska, A., Wang, C., Buer, J., et al. (2007) · Nature Genetics · doi:10.1038/ng1937 · Cited by 426 · cited 1×
“The mechanism behind replicative exhaustion involves the progressive erosion of the telomeres after many replication cycles along with or without elevated expression of cyclin dependent kinase inhibitors (Choudhury et al., 2007).”
BackgroundγH2AX and MDC1: Anchoring the DNA-damage-response machinery to broken chromosomes
Stucki, M., & Jackson, S. P. (2006) · DNA Repair · doi:10.1016/j.dnarep.2006.01.012 · Cited by 412
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence
Lin, H.-K., Chen, Z., Wang, G., Nardella, C., Lee, S.-W., Chan, C.-H., Yang, W.-L., Wang, J., Egia, A., Nakayama, K. I., et al. (2010) · Nature · doi:10.1038/nature08815 · Cited by 400 · cited 1×
“The aim of these therapeutics would be to stabilize the CDK inhibitor p27 (Lin et al., 2010) or to directly target CDK2 itself and induce senescence (Senderowicz, 2003a, b).”
BackgroundMany roads lead to oncogene-induced senescence
Courtois-Cox, S., Jones, S. L., & Cichowski, K. (2008) · Oncogene · doi:10.1038/sj.onc.1210950 · Cited by 397 · cited 1×
“While there are many different oncogenes that can induce senescence, most appear to utilize a similar signaling cascade via activation of ATM/p53/RB pathway (reviewed in (Caino et al., 2009; Courtois-Cox et al., 2008)).”
BackgroundCellular senescence as a tumor-suppressor mechanism
Campisi, J. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)82148-6 · Cited by 390 · cited 1×
“In response to the activation of an oncogene or a loss of a tumor suppressor activity, the senescence signaling cascade is initiated to protect the integrity of the cell and restrain neoplastic growth (Campisi, 2001).”
BackgroundAlimonti, A., Nardella, C., Chen, Z., Clohessy, J. G., Carracedo, A., Trotman, L. C., Cheng, K., Varmeh, S., Kozma, S. C., Thomas, G., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40535 · Cited by 374
Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302 · cited 5×
“Comprehensive studies of transcriptional responses to genotoxic stress induced by cancer therapeutics have identified a spectrum of highly-induced secreted proteins originating in the tumor microenvironment that comprise several hundred factors (Bavik et al., 2006; Coppe et al., 2008; Kuilman et al., 2008).”
BackgroundInfluentialSelf-citationDuan, J., Duan, J., Zhang, Z., & Tong, T. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.01.010 · Cited by 229
Efeyan, A., Ortega-Molina, A., Velasco-Miguel, S., Herranz, D., Vassilev, L. T., & Serrano, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0200 · Cited by 140 · cited 1×
“These and other results have led to the development of drugs which attempt to restore p53 activity (Efeyan et al., 2007; Kumamoto et al., 2008).”
ResultWei, W., Herbig, U., Wei, S., Dutriaux, A., & Sedivy, J. M. (2003) · The EMBO Reports · doi:10.1038/sj.embor.7400001 · Cited by 88 · cited 1×
“Additionally, it was identified that alterations in both p21 and p53 promote the bypass of senescence (Wei et al., 2003).”
Background
Cited by
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
Targeting cellular senescence with senotherapeutics: senolytics and senomorphics
Zhang, L., Pitcher, L. E., Prahalad, V., Niedernhofer, L. J., & Robbins, P. D. (2023) · The FEBS Journal · doi:10.1111/febs.16350 · Cited by 621
The Multifaceted p21 (Cip1/Waf1/CDKN1A) in Cell Differentiation, Migration and Cancer Therapy
Kreis, N.-N., Louwen, F., & Yuan, J. (2019) · Cancers · doi:10.3390/cancers11091220 · Cited by 298
Mechanisms of Taxane Resistance
Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198
Senescence and senotherapeutics: a new field in cancer therapy
Myrianthopoulos, V., Evangelou, K., Vasileiou, P. V. S., Cooks, T., Vassilakopoulos, T. P., Pangalis, G. A., Kouloukoussa, M., Kittas, C., Georgakilas, A. G., & Gorgoulis, V. G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.006 · Cited by 160
Metadata
- Authors
- Gordon, R. R., & Nelson, P. S.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 15
- Issue
- 1-2
- Pages
- 123-131
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W2071735670
- Cited by
- 134
- References
- 49
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.